CC
SRRA

Claybrook Capital’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Claybrook Capital’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-84
Closed -$4K – 746
2018
Q4 		$4K Buy
+84
New +$5.37K ﹤0.01% 601

Other funds holding SRRA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Claybrook Capital's SRRA Position: Q1 2019 in Review

Claybrook Capital sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q1 2019, closing a stake of 84 shares — an estimated $4K sold.

Claybrook Capital first reported a position in SRRA in Q4 2018 and held it in 1 quarter. The position peaked at $4K in Q4 2018. 59 funds tracked by Wall St. Rank hold SRRA as of Q1 2019.

  • Claybrook Capital reported no remaining Sierra Oncology, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Claybrook Capital sold 84 Sierra Oncology, Inc. Common Stock shares in Q1 2019, an estimated $4K.
  • Claybrook Capital first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2018 and held it in 1 quarter.
  • Claybrook Capital's Sierra Oncology, Inc. Common Stock position peaked at $4K in Q4 2018.
  • 59 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q1 2019.

Based on Claybrook Capital's 13F filing for Q1 2019, filed 15 May 2019.